These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18607107)

  • 1. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone.
    Charach G; Grosskopf I; Weintraub M
    Digestion; 2008; 77(3-4):198-200. PubMed ID: 18607107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA; Kim E; Moodie J
    Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Crohn's disease in a patient taking etanercept.
    Oh J; Arkfeld DG; Horwitz DA
    J Rheumatol; 2005 Apr; 32(4):752-3. PubMed ID: 15801037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
    Dhib-Jalbut S
    Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
    Bains SN; Hsieh FH; Rensel MR; Radojicic C; Katz HT; Inamdar SR; Lang DM
    Ann Allergy Asthma Immunol; 2010 Apr; 104(4):321-5. PubMed ID: 20408342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis].
    Petrova LV; Boĭko AN; Batysheva TT; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):41-5. PubMed ID: 21311486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate in multiple sclerosis.
    Mezzapesa DM; Rovaris M; Filippi M
    Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study.
    Soares Almeida LM; Requena L; Kutzner H; Angulo J; de Sa J; Pignatelli J
    J Am Acad Dermatol; 2006 Dec; 55(6):968-74. PubMed ID: 17097393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
    Moreau T
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 18. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation.
    Fragoso YD
    Expert Opin Drug Saf; 2014 Dec; 13(12):1743-8. PubMed ID: 25176273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New options for early treatment of multiple sclerosis.
    Tintoré M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.